Welcome to our dedicated page for Vanda Pharma SEC filings (Ticker: VNDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
HETLIOZ clinical data charts, Fanapt revenue disclosures, and Phase III trial outcomes for Vanda Pharmaceuticals rarely fit on a single page—they sprawl across hundreds of lines in each Form 10-K and 10-Q. If tracking FDA milestones or insider sentiment feels overwhelming, you’re not alone. Vanda’s science-heavy language, coupled with dozens of 8-K study updates, makes locating critical numbers time-consuming.
Stock Titan solves that problem. Our platform delivers real-time alerts the moment a Vanda Pharmaceuticals quarterly earnings report 10-Q filing or an 8-K material events report posts to EDGAR. AI-powered summaries translate dense pharmacokinetic tables into clear bullet points, while expert commentary flags what moves the stock. Need Vanda Pharmaceuticals insider trading Form 4 transactions? We surface every executive stock transaction instantly and keep a running log of Vanda Pharmaceuticals Form 4 insider transactions real-time.
Whether you’re comparing segment sales, reviewing Vanda Pharmaceuticals annual report 10-K simplified, or studying Vanda Pharmaceuticals proxy statement executive compensation, the insights you need sit one click away. Our tools answer the questions investors actually ask—“understanding Vanda Pharmaceuticals SEC documents with AI” or “Vanda Pharmaceuticals earnings report filing analysis”—and connect them to practical use cases like monitoring drug launch timelines or evaluating R&D burn rates. From Vanda Pharmaceuticals executive stock transactions Form 4 to Vanda Pharmaceuticals SEC filings explained simply, every document is searchable, summarized, and ready to guide your next decision.
Vanda Pharmaceuticals (VNDA) reported a larger quarterly loss despite higher sales. Net product sales were $56.3 million in Q3 2025, up from $47.7 million a year ago. Sales by product: Fanapt $31.2 million, HETLIOZ $18.0 million, and PONVORY $7.0 million.
Operating expenses rose sharply, with selling, general and administrative at $60.3 million (from $37.6 million) and research and development at $22.6 million (from $16.8 million). Loss from operations was $31.3 million; net loss was $22.6 million, or $0.38 per share. For the nine months, revenue reached $158.9 million with a net loss of $79.3 million. Operating cash flow was an outflow of $80.0 million year-to-date.
Liquidity remained significant: cash and cash equivalents were $70.0 million and marketable securities were $223.7 million as of September 30, 2025. Total assets were $601.1 million and stockholders’ equity was $466.0 million. The company noted HETLIOZ sales may be variable and could decline in future periods related to generic competition. Shares outstanding were 59,096,630 as of October 23, 2025.
Vanda Pharmaceuticals (VNDA) furnished an 8‑K stating it issued a press release and is holding a conference call regarding results of operations and financial condition for the quarter ended September 30, 2025.
The press release is included as Exhibit 99.1 and, along with Item 2.02, is furnished and not deemed “filed” under the Exchange Act. The company also included standard forward‑looking statements cautions, directing readers to risk factors in its periodic SEC reports.
Mihael H. Polymeropoulos, identified as President and CEO (also listed as a director and chairman), reported a purchase of 10,000 shares of Vanda Pharmaceuticals common stock on 08/07/2025 at $4.15 per share. After this purchase he beneficially owns 2,335,731 shares. The Form 4 discloses a direct insider buy by the company’s chief executive, increasing his reported stake.
FAQ
What is the current stock price of Vanda Pharma (VNDA)?
What is the market cap of Vanda Pharma (VNDA)?
